# A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

> **NCT06807268** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 150 (estimated)

## Conditions studied

- Eczema

## Interventions

- **DRUG:** Abrocitinib
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06807268
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-24
- **Primary completion:** 2027-05-02
- **Final completion:** 2027-05-02
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06807268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06807268, "A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06807268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*